Prof. PeptideProf. Peptide
Guide

Retatrutide Dosage in 2026: Clinic Doses and Trial Doses

Retatrutide is Eli Lilly's investigational once-weekly injection that activates the GLP-1, GIP and glucagon receptors [5][15]. Clinics that offer it sell weekly injections of 2,000 to 12,000 mcg (2–12 mg) [17]; its peer-reviewed Phase 3 trials used 4,000, 9,000 and 12,000 mcg (4, 9 and 12 mg) once weekly [5][6][7].

No approved dose

Retatrutide has no prescribing information and no boxed warning. The doses below are what clinics publish and what the trials administered, reported as their sources state them.

How is retatrutide dosed?

Clinics that offer retatrutide sell single weekly injections in a reported range of 2,000 to 12,000 mcg (2–12 mg), without a published step schedule [17][18][19]. No label or trial has set a dose outside a study.

The clinics in the table are representative of the clinic pages on retatrutide, which include the largest online peptide and weight-loss clinics. These are clinic practices, not tested protocols.

ClinicDose as publishedSchedulePrice
61Five Health & Wellness [17]Single weekly injections of 2,000, 4,000, 6,000, 10,000 or 12,000 mcg (2, 4, 6, 10 or 12 mg)No step schedule, starting dose or course length published$99 to $179 per injection
Beyond Concierge Healthcare [18]Not publishedDose adjustments included in the programFrom $499 a month
California Trim Clinic [19]Not publishedGradual dose escalation, “structured dosing”Not published
  • One clinic writes that retatrutide “has no official prescribing dose because it's still investigational” [20]; another that “there is no FDA-approved dosing schedule yet” [22].
  • No clinic publishes a maximum dose, a step schedule or a course length for its own patients [17][18][19].

The side effects clinics list are under What are the side effects of retatrutide at each dose?, its legal status under Is retatrutide legal?, and the trial doses, with the ladder some clinics restate from them, under What do human studies show about retatrutide dosing?

How is retatrutide taken?

Clinics that offer retatrutide sell a weekly subcutaneous injection in the thigh, stomach or arm, taken at home [17]. No approved label sets a missed-dose rule.

The retatrutide reconstitution calculator works out what a given volume of bacteriostatic water does to a research-grade vial’s concentration and how many syringe units a given amount takes; it does not set a dose. The how much bac water for retatrutide FAQ sets out the same arithmetic for common vial sizes.

What are the side effects of retatrutide at each dose?

Retatrutide's most common side effects in its trials are stomach and gut effects that rise with dose: in the peer-reviewed TRIUMPH-2 trial, nausea affected 14%, 21% and 28% at 4,000, 9,000 and 12,000 mcg (4, 9 and 12 mg) vs 8% on placebo, and diarrhea 27%, 34% and 34% vs 13% [6]. No approved label lists its warnings.

  • Dysesthesia, a tingling, burning or prickling skin sensation: 4%, 6% and 7% vs 1% on placebo in TRIUMPH-2 [6]; in the head-to-head trial, Lilly reported 4.8% and 6.5% on retatrutide 9,000 and 12,000 mcg (9 and 12 mg) vs 2.7% on Ozempic 2,000 mcg (2 mg) [12].
  • Low blood pressure: 1%, 5% and 6% vs under 1% on placebo (TRIUMPH-2) [6].
  • Heart rate rose with dose in the Phase 2 obesity trial, peaking at 24 weeks and declining after [1].
  • Stopping for side effects: 4%, 12% and 8% vs 5% on placebo in TRIUMPH-2 [6]; 2–5% vs 0% in TRANSCEND-T2D-1 [7]. Deaths in both trials were judged unrelated [6][7].
  • Starting dose: in Phase 2, gastrointestinal events were partly mitigated by a 2,000 mcg (2 mg) rather than a 4,000 mcg (4 mg) start [1].

What clinics report

  • Clinics list bloating, loose stool, nausea and vomiting, and a faster heart rate that is often dose-related [17][25]; one describes nausea as eased by smaller, lower-fat meals, stopping at first fullness [21].
  • Clinics describe retatrutide as likely to be unsuitable with a family history of medullary thyroid cancer or MEN 2 [26], and report that the trials stopped it for pregnancy, pancreatitis, severe allergic reactions or a BMI of 18.5 or below [23].
  • Products sold outside trials: clinics warn of unknown ingredients, dosing errors and contamination [24], and of counterfeit product and inaccurate concentrations [25]. Lilly states that illicit product may contain unknown ingredients or the wrong amount of active ingredient [15].

What do human studies show about retatrutide dosing?

Retatrutide's doses have been tested in randomized trials: four peer-reviewed Phase 3 papers in 2026, in obesity, obesity with type 2 diabetes, type 2 diabetes and sleep apnea, used 4,000, 9,000 and 12,000 mcg (4, 9 and 12 mg) once weekly [5][6][7][8], after Phase 2 trials of 500 to 12,000 mcg (12 mg) [1][2] and a Phase 1b dose study [3].

The Phase 3 abstracts and registry arms give each arm's maintenance dose but not the step-by-step escalation to it [5][6][7]; the only peer-reviewed escalation is Phase 2's, a 2,000 or 4,000 mcg (2 or 4 mg) start with steps every 4 weeks where applicable [1][4]. All the trials were funded by Eli Lilly [1][5][6][7].

Clinics that describe the trials restate a ladder starting at 2,000 mcg (2 mg) a week and stepping up every 4 weeks to 12,000 mcg (12 mg) [20][22][23]. The restated ladders differ in the middle steps (8,000 mcg (8 mg) in one, 6,000 then 9,000 mcg (6 then 9 mg) in another) and in when the top dose is reached, at week 13 in one and after 16 weeks in another [20][23].

Retatrutide's half-life is about 6 days, measured in the Phase 1b study, whose authors concluded it suits once-weekly dosing [3]. At a 6-day half-life a weekly interval leaves roughly half of each dose in circulation when the next one lands, so levels build over about four to five weeks before settling. The GLP-1 half-life calculator models that build-up against semaglutide and tirzepatide.

TRIUMPH-1 — obesity without diabetes

NCT05929066

N Engl J Med 2026 [5]

Doses: 2,339 adults randomized to placebo or 4,000, 9,000 or 12,000 mcg (4, 9 or 12 mg) once weekly for 80 weeks. The abstract and the registry arms name each maintenance dose but give no escalation schedule [5].

Result: Mean weight change −17.6%, −23.7% and −25.0% at 4,000, 9,000 and 12,000 mcg (4, 9 and 12 mg) vs −3.9% on placebo. In the 574-person knee-osteoarthritis subgroup, WOMAC pain (scored 1 to 10) changed by −3.2, −3.5 and −3.6 vs −1.9 [5].

Safety: Gastrointestinal events were the most common adverse events [5].

TRIUMPH-2 — obesity with type 2 diabetes

NCT05929079

Lancet 2026 [6]

Doses: 1,152 adults randomized to placebo or 4,000, 9,000 or 12,000 mcg (4, 9 or 12 mg) once weekly for 80 weeks [6].

Result: Mean weight change −11.9%, −16.8% and −18.8% vs −5.1% on placebo [6].

Safety: Nausea 14%, 21% and 28% vs 8%; diarrhea 27%, 34% and 34% vs 13%; dysesthesia 4%, 6% and 7% vs 1%; low blood pressure 1%, 5% and 6% vs under 1%. Permanent discontinuation for adverse events or death 4%, 12% and 8% vs 5%. Two, three and one participants died in the 4,000, 9,000 and 12,000 mcg (4, 9 and 12 mg) groups and one on placebo; all deaths were judged unrelated [6].

TRANSCEND-T2D-1 — type 2 diabetes

NCT06354660

Lancet 2026 [7]

Doses: 537 adults on diet and exercise alone, randomized to placebo or 4,000, 9,000 or 12,000 mcg (4, 9 or 12 mg) once weekly for 40 weeks, at 48 sites in the USA, Mexico and India [7].

Result: HbA1c −1.69, −1.86 and −1.94 points vs −0.81 on placebo; weight −11.5%, −13.9% and −15.3% vs −2.6% [7].

Safety: Discontinuation for adverse events 2–5% on retatrutide vs 0% on placebo; gastrointestinal events mild to moderate and subsiding over time; no severe hypoglycemia; two deaths, both at 4,000 mcg (4 mg), judged unrelated [7].

TRIUMPH-1-OSA and TRIUMPH-2-OSA — obstructive sleep apnea

NCT05929066, NCT05929079

N Engl J Med 2026 [8]

Doses: 243 adults without diabetes and 448 with type 2 diabetes, moderate-to-severe sleep apnea, 4,000, 9,000 or 12,000 mcg (4, 9 or 12 mg) once weekly for 80 weeks [8].

Result: Apnea-hypopnea index −22.9, −34.3 and −31.7 events per hour vs −9.9 on placebo without diabetes, and −19.2, −24.7 and −25.4 vs −10.3 with diabetes [8].

Safety: Reported in the parent TRIUMPH-1 and TRIUMPH-2 papers [5][6].

Phase 2 — obesity

NCT04881760

N Engl J Med 2023 [1]

Doses: 338 adults, 48 weeks, in six arms: 1,000 mcg (1 mg); 4,000 mcg (4 mg) started at 2,000 mcg (2 mg) or at 4,000 mcg (4 mg); 8,000 mcg (8 mg) started at 2,000 or 4,000 mcg (2 or 4 mg); and 12,000 mcg (12 mg) started at 2,000 mcg (2 mg); or placebo [1]. Where applicable, doses were escalated every 4 weeks [4].

Result: Weight change at 48 weeks −8.7%, −17.1%, −22.8% and −24.2% at 1,000, 4,000, 8,000 and 12,000 mcg (1, 4, 8 and 12 mg) vs −2.1% on placebo [1].

Safety: Gastrointestinal events were the most common, dose-related and mostly mild to moderate, and were partly mitigated by the lower 2,000 mcg (2 mg) starting dose; heart rate rose with dose, peaking at 24 weeks and declining after [1]. The registry's posted results list nausea in 28 of 62 participants at 12,000 mcg (12 mg) vs 8 of 70 on placebo, and vomiting in 12 of 62 vs 1 of 70 [9].

Phase 2 — type 2 diabetes

NCT04867785

Lancet 2023 [2]

Doses: 281 adults, 36 weeks: placebo, dulaglutide 1,500 mcg (1.5 mg), or retatrutide 500 mcg, 4,000 mcg (4 mg), 8,000 mcg (8 mg) or 12,000 mcg (12 mg) once weekly, the 4,000 and 8,000 mcg (4 and 8 mg) arms each split between two escalation strategies [2].

Result: HbA1c at 24 weeks fell by up to 2.02 points at 12,000 mcg (12 mg) vs 0.01 on placebo and 1.41 on dulaglutide; body weight fell by up to 16.94% over 36 weeks [2].

Safety: Nausea, diarrhea, vomiting and constipation together affected 35% of retatrutide participants vs 13% on placebo [2].

Phase 1b — type 2 diabetes

Lancet 2022 [3]

Doses: 72 people with type 2 diabetes, 500 to 12,000 mcg (12 mg) once weekly for 12 weeks [3].

Result: Half-life about 6 days; the authors concluded the pharmacokinetics suit once-weekly dosing [3].

Safety: Adverse events in 63% vs 54% on placebo, mostly gastrointestinal [3].

Reported by Lilly only, not yet peer-reviewed

  • TRANSCEND-T2D-2, head to head with Ozempic: Type 2 diabetes, 80 weeks, retatrutide 9,000 and 12,000 mcg (9 and 12 mg) vs Ozempic 2,000 mcg (2 mg): HbA1c −2.2% with both retatrutide doses vs −1.8%; weight −19.5% and −20.9% vs −9.4%; dysesthesia 4.8% and 6.5% vs 2.7%; discontinuation for adverse events 4.8% and 7.9% vs 2.7%. Lilly release, October 28, 2026 [12].
  • TRIUMPH-3, obesity with cardiovascular disease: 1,946 enrolled; primary outcome weight change at 80 weeks. Lilly reported up to 22.6% mean weight loss and major cardiovascular events less frequent than anticipated in both arms. Lilly release, July 23, 2026; no results posted on the registry [11].
  • TRIUMPH-4, obesity with knee osteoarthritis: 445 enrolled, retatrutide 9,000 or 12,000 mcg (9 or 12 mg) vs placebo for 68 weeks; Lilly reported weight loss of up to a mean 28.7% and WOMAC pain reduced by up to 4.5 points. Lilly release, December 11, 2025 [10].

No cardiovascular-outcomes trial has reported: TRIUMPH-Outcomes, registered for 10,000 participants, is estimated to complete its primary phase in February 2029 [29].

FAQ

What is the dosage of retatrutide?
Retatrutide has no approved dose. Clinics that offer it sell weekly subcutaneous injections of 2,000 to 12,000 mcg (2–12 mg), and clinics that describe its trials restate a 2,000 mcg (2 mg) start stepped up every 4 weeks. Its Phase 3 trials used maintenance doses of 4,000, 9,000 and 12,000 mcg (4, 9 and 12 mg) once weekly.
What is the starting dose of retatrutide?
Clinics that describe retatrutide's trials restate a starting dose of 2,000 mcg (2 mg) once weekly. In the Phase 2 obesity trial, arms started at 2,000 mcg (2 mg) or 4,000 mcg (4 mg), and gastrointestinal events were partly mitigated by the lower start. The Phase 3 papers' abstracts do not set out their escalation schedules.
How often is retatrutide dosed?
Once weekly, in every published trial and on every clinic page that states a schedule. Retatrutide's half-life is about 6 days, measured in its Phase 1b study, whose authors concluded the pharmacokinetics suit once-weekly dosing. At that half-life, levels build over roughly four to five weekly doses before settling.
What is the highest dose of retatrutide studied?
12,000 mcg (12 mg) once weekly, the top arm in the Phase 1b, Phase 2 and Phase 3 trials. In TRIUMPH-1, adults with obesity without diabetes on 12,000 mcg (12 mg) lost a mean 25.0% of body weight over 80 weeks against 3.9% on placebo; clinics that offer retatrutide publish the same 12,000 mcg (12 mg) top tier.
What are the side effects of retatrutide at higher doses?
In the peer-reviewed TRIUMPH-2 trial, nausea affected 14%, 21% and 28% at 4,000, 9,000 and 12,000 mcg (4, 9 and 12 mg) against 8% on placebo; dysesthesia, a tingling or burning skin sensation, 4%, 6% and 7% against 1%; and low blood pressure 1%, 5% and 6% against under 1%.
Can retatrutide be compounded or prescribed?
Retatrutide is not approved anywhere, and FDA states it cannot be used in compounding under federal law. Most clinics say it cannot be prescribed outside a clinical trial; a few describe their own compounded programs. Research-grade retatrutide is sold for laboratory research use only, not for human use.

References

  1. Jastreboff AM, Kaplan LM, Frías JP, et al. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023;389:514–526. PMID 37366315. ClinicalTrials.gov NCT04881760. https://doi.org/10.1056/NEJMoa2301972
  2. Rosenstock J, Frías J, Jastreboff AM, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. Lancet. 2023;402:529–544. PMID 37385280. NCT04867785. https://doi.org/10.1016/S0140-6736(23)01053-X
  3. Urva S, Coskun T, Loh MT, et al. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial. Lancet. 2022;400:1869–1881. PMID 36354040. https://pubmed.ncbi.nlm.nih.gov/36354040/
  4. Sanyal AJ, Kaplan LM, Frías JP, et al. Retatrutide for adults with metabolic dysfunction-associated steatotic liver disease: a Phase 2 trial. Nat Med. 2024;30:1235–1244. PMID 38858523. Cited for the Phase 2 escalation interval. https://pubmed.ncbi.nlm.nih.gov/38858523/
  5. Jastreboff AM, Kaplan LM, Davies MJ, et al. Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity (TRIUMPH-1). N Engl J Med. 2026. PMID 42814954. NCT05929066. https://doi.org/10.1056/NEJMoa2604169
  6. Bellido V, le Roux CW, Ekinci EI, et al. Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial. Lancet. 2026;408:1455–1472. PMID 42810372. NCT05929079. https://pubmed.ncbi.nlm.nih.gov/42810372/
  7. Bajaj HS, Welch M, Shah P, et al. Efficacy and safety of retatrutide in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial. Lancet. 2026;407:2402–2413. PMID 42250575. NCT06354660. https://pubmed.ncbi.nlm.nih.gov/42250575/
  8. Grunstein RR, Somers VK, Azarbarzin A, et al. Retatrutide Once Weekly for Treatment of Obstructive Sleep Apnea (TRIUMPH-1-OSA and TRIUMPH-2-OSA). N Engl J Med. 2026. PMID 42904878. https://pubmed.ncbi.nlm.nih.gov/42904878/
  9. ClinicalTrials.gov. NCT04881760, posted results (adverse events). Cited for the nausea and vomiting counts. https://clinicaltrials.gov/study/NCT04881760
  10. Eli Lilly and Company. TRIUMPH-4 topline results, investor press release, December 11, 2025. Not peer-reviewed. NCT05931367. https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-weight-loss-average
  11. Eli Lilly and Company. TRIUMPH-2 and TRIUMPH-3 topline results and the BLA plan, PR Newswire, July 23, 2026; read November 5, 2026. Not peer-reviewed. TRIUMPH-3: NCT05882045. https://www.prnewswire.com/news-releases/lillys-triple-agonist-retatrutide-successful-in-two-additional-phase-3-obesity-trials-delivering-significant-improvements-in-weight-and-a1c-302832674.html
  12. Eli Lilly and Company. TRANSCEND-T2D-2 topline results, PR Newswire, October 28, 2026; read November 5, 2026. Not peer-reviewed. https://www.prnewswire.com/news-releases/lillys-retatrutide-delivered-greater-a1c-reduction-and-more-than-double-the-weight-loss-of-ozempics-highest-approved-dose-in-head-to-head-trial-302921328.html
  13. U.S. Food and Drug Administration. FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. Content current as of October 1, 2026; read November 5, 2026. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
  14. U.S. Food and Drug Administration. Warning Letter: GLP-1 Solution, reference 715883, September 9, 2025. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/glp-1-solution-715883-09092025
  15. Eli Lilly and Company. What to know about retatrutide. Last updated October 2026; read November 5, 2026. https://www.lilly.com/news/stories/what-to-know-about-retatrutide
  16. World Anti-Doping Agency. 2026 Prohibited List, S0 Non-approved substances. Valid January 1, 2026. https://www.wada-ama.org/en/prohibited-list
  17. 61Five Health & Wellness, Nashville, Franklin and Murfreesboro, Tennessee. Read November 5 and 6, 2026. Cited for its own dose tiers, prices, route, status wording and side-effect list. https://61five.com/nashville-retatrutide/
  18. Beyond Concierge Healthcare, Palm Beach, Florida. Read November 5 and 6, 2026. Cited for its own program price and dose adjustments. https://beyondconciergehealthcare.com/retatrutide-palm-beach
  19. California Trim Clinic; page dated September 18, 2026, read November 3, 2026. Cited for its own program and dosing description. https://www.californiatrimclinic.com/what-are-the-side-effects-of-retatrutide-and-what-should-you-expect-before-starting/
  20. Pru (joinpru.com), retatrutide dosage, updated July 9, 2026; read November 5, 2026. Cited for “no official prescribing dose” and its restated trial ladder. https://joinpru.com/blog/retatrutide-dosage
  21. Pru (joinpru.com), retatrutide side effects, updated July 9, 2026; read November 5, 2026. Cited for its nausea-management line. https://joinpru.com/blog/retatrutide-side-effects
  22. Ro (ro.co); reviewed by Raagini Suresh Yedidi, MD; updated July 20, 2026. Read November 3 and 6, 2026. Cited for its status statements and its restated 4-weekly trial steps. https://ro.co/weight-loss/retatrutide-dosing/
  23. Noom (noom.com); reviewed by Odhett Cojocaru, MD; May 6, 2026. Read November 3 and 5, 2026. Cited for its restated trial ladder and trial safety figures. https://www.noom.com/blog/weight-management/retatrutide-dosing/
  24. InCare (incarenow.com), September 13, 2026. Read November 3, 2026. Cited for its own status and caution statements. https://www.incarenow.com/how-to-access-retatrutide-availability-in-the-usa-safely/
  25. Relive Health (relivehealth.com), April 16, 2026. Read November 3, 2026. Cited for its own status, side-effect and caution statements. https://relivehealth.com/peptides/retatrutide-for-weight-loss-is-it-safe-available-and-legal-to-buy-in-2026/
  26. Klinic (klinic.com). Read November 3, 2026. Cited for its own status, side-effect and caution statements. https://klinic.com/retatrutide
  27. Philadelphia Medical Weight Loss. Read November 5, 2026. Cited for its own status statement. https://philadelphiamedicalweightloss.com/retatrutide-philadelphia/
  28. ClinicalTrials.gov. Pre-approval Expanded Access of Retatrutide (LY3437943), NCT07629401. https://clinicaltrials.gov/study/NCT07629401
  29. ClinicalTrials.gov. TRIUMPH-Outcomes: cardiovascular and kidney outcomes in adults living with obesity, NCT06383390; 10,000 participants estimated, primary completion February 2029 (estimated). Read November 5, 2026. https://clinicaltrials.gov/study/NCT06383390

Affiliate disclosure: Prof. Peptide earns a commission on purchases and sign-ups made through its links and codes, at no extra cost to the buyer. Commissions never decide which vendors are listed, how they are ranked or verified, or what Prof. Peptide concludes.

Checked and updated